Mostrar el registro sencillo del ítem

dc.contributor.authorContreras-Virues, Mario Raul
dc.contributor.authorVera Jiménez, José Carlos 
dc.contributor.authorBrea-Salvago, Juan Francisco
dc.contributor.authorMoreno Corbacho, Ignacio 
dc.contributor.authorGarcía Ortiz, José Carlos 
dc.contributor.authorDíaz Gómez, Alfredo Luis 
dc.contributor.authorRibelles García, Antonio 
dc.contributor.authorPérez Arana, Gonzalo Martín 
dc.contributor.otherAnatomía Patológica, Biología Celular, Histología, Historia de la Ciencia, Medicina Legal y Forense y Toxicologíaes_ES
dc.contributor.otherAnatomía y Embriología Humanaes_ES
dc.date.accessioned2026-07-28T10:15:23Z
dc.date.available2026-07-28T10:15:23Z
dc.date.issued2026
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/10498/40106
dc.description.abstractBackground/Objectives: Type 2 diabetes mellitus (T2DM) substantially increases the risk of infection and sepsis while modifying host immune responses, clinical presenta-tion, and biomarker performance. This review summarizes the pathophysiological mechanisms by which T2DM interferes with the early recognition of sepsis and criti-cally evaluates the performance of conventional and emerging biomarkers in this spe-cific population. Methods: A narrative review of the literature was conducted using PubMed, Scopus, and Web of Science. Original studies, systematic reviews, me-ta-analyses, international guidelines, and landmark publications addressing the inter-action between T2DM, sepsis, immune dysfunction, and sepsis biomarkers were criti-cally analyzed. Results: Chronic hyperglycemia induces immune dysregulation, endo-thelial dysfunction, and persistent low-grade inflammation, resulting in atypical infec-tion presentations and reduced sensitivity of conventional clinical assessment tools. Baseline elevations and altered kinetics of C-reactive protein, procalcitonin, interleu-kin-6, and other inflammatory biomarkers may reduce their diagnostic specificity. Lactate retains prognostic value but should be interpreted cautiously in patients with diabetic ketoacidosis or other metabolic disturbances. Emerging biomarkers, including presepsin, pro-adrenomedullin, soluble urokinase plasminogen activator receptor, cell-free DNA, and 16S rRNA, show promising diagnostic potential, although evidence in diabetic populations remains limited. Conclusions: T2DM represents a distinct clin-ical phenotype in sepsis that requires individualized interpretation of biomarkers. Multimarker strategies integrating clinical, metabolic, and laboratory data may im-prove early sepsis recognition, but prospective validation studies in diabetic popula-tions are still needed.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/4.0/*
dc.sourceJournal of Clinical Medicine - 2026, Vol. 14es_ES
dc.subjectSepsises_ES
dc.subjectT2DMes_ES
dc.subjectBiomarkerses_ES
dc.subjectInmune dysfunctiones_ES
dc.subjectearly diagnosises_ES
dc.titleInterference of Type 2 Diabetes Mellitus in the Early Diagnosis of Sepsis: Clinical Challenges and Biomarkerses_ES
dc.typepreprintes_ES
dc.rights.accessRightsopen accesses_ES
dc.type.hasVersionSMURes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-CompartirIgual 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución-CompartirIgual 4.0 Internacional